MedPath

Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder

Not Applicable
Conditions
Bipolar Disorder
Registration Number
NCT00188838
Lead Sponsor
University Health Network, Toronto
Brief Summary

To examine the impact of cognitive-behavioural therapy on both the episodic and functional outcome of bipolar disorder, in combination with pharmacotherapy.

Primary Hypothesis is twofold:

1. Cognitive Behavioural Therapy will reduce the total symptom burden, as measured both by percentage of time spent ill (both syndromic and subsyndromal) and number of episodes, as compared to psychoeducation

2. Cognitive behavioural therapy will reduce social and occupational disability to a greater extent than psychoeducation.

Detailed Description

Objective:

To compare the impact of cognitive -behavioral therapy to that of properly structured psycho education on the 'illness burden' and functional outcome of bipolar disorder, in combination with pharmacotherapy.

Interventions:

Subjects will be randomized to either a "control" treatment group cosisting of 6 sessions of group psycho-education (topics include illness recognition, treatment approaches, and monitoring and coping strategies; based on manual by Bauer \& McBride, 2002: Life Goals Phase I) or they will be randomized to the "experimental" treatment group: 20 sessions of individual Cognitive Behavioural Therapy for Bipolar Disorder (topics include limited psychoeducation, activity scheduling/behavioural interventions, cognitive techniques, including thought monitoring and challenges to dysfunctional assumptions and other coping techniques; based on manual by Lam et al., 1999: Cognitive Therapy for Bipolar Disorder)

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
210
Inclusion Criteria
  1. Bipolar I or II
  2. Currently either in remission or subsyndromally ill (Hamilton Depression Scale-17<14; Clinician Administered Rating Scale for Mania<12).
  3. Age eighteen to sixty.
  4. Significant symptoms and/or episodes on at least two occasions in the past three years.
  5. Grade six education, able to understand English, and Folstein Minimental Score Exam > 26 to ensure cognitive ability to participate.
  6. On mood-stabilizing medication.
Read More
Exclusion Criteria
  1. Substance dependence meeting Diagnostic and Statistical Manual of Mental Disorders-IV criteria within the last three months.
  2. Acutely highly suicidal or homicidal.
  3. Serious other medical condition that would render pharmacotherapy or psychotherapy very difficult such as cancer, severe diabetes, etc.
  4. Severe antisocial or borderline personality disorder (personality disorder per se is not exclusionary). Subjects may have other axis I disorders, but bipolar disorder must be the principal disorder requiring treatment.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Longitudinal Interval Follow-up Evaluation (LIFE; Keller et al, 1987).
Modified Social Adjustment Scale (SAS II-B; Bauer, 2001)
***Note: all primary outcomes obtained prospectively every 3 months for 18 months
Secondary Outcome Measures
NameTimeMethod
Activity and Utilisation Questionnaire
Medication Compliance scale
Intensity of Somatotherapy Index
Clinician Administered Rating Scale for Mania
Hamilton Depression Rating Scale
Quality of Life, Enjoyment, and Satisfaction Questionnaire
Dysfunctional Attitudes Scale
Patient Satisfaction Index
Coping Inventory for Prodromes of Mania
Khavari Alcohol Test.
*****Note: all secondary outcomes measured prospectively over 18 months

Trial Locations

Locations (6)

University of British Columbia, Department of Psychiatry

🇨🇦

Vancouver, British Columbia, Canada

Douglas Hospital-McGill University

🇨🇦

Verdun, Quebec, Canada

McGill University Health Centre

🇨🇦

Montreal, Quebec, Canada

University Health Network

🇨🇦

Toronto, Ontario, Canada

Centre for Addiction and Mental Health

🇨🇦

Toronto, Ontario, Canada

St. Joseph's Healthcare, CMHS

🇨🇦

Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath